mTOR Cancer Research Results

mTOR, mammalian target of rapamycin: Click to Expand ⟱
Source: HalifaxProj (inhibit)
Type:
mTOR (mechanistic target of rapamycin) is a central regulator of cell growth, proliferation, metabolism, and survival. It is a serine/threonine kinase that integrates signals from nutrients, growth factors, and cellular energy status.
mTOR promotes protein synthesis and cell growth by activating downstream targets such as S6 kinase and 4E-BP1. In cancer, this pathway can become hyperactivated, leading to uncontrolled cell proliferation.

mTor Inhibitors:
-rapamycin (Sirolimus): classic natural product mTOR inhibitor
-Curcumin
-Resveratrol
-Epigallocatechin Gallate (EGCG)
-Honokiol
NSCLC, Non-small Cell Lung Cancer: Click to Expand ⟱
Non-small Cell Lung Cancer
Scientific Papers found: Click to Expand⟱
4678- Ash,    Identification of Withaferin A as a Potential Candidate for Anti-Cancer Therapy in Non-Small Cell Lung Cancer
- vitro+vivo, NSCLC, H1975
ROS↑, AntiTum↑, CSCs↓, mTOR↓, STAT3↓, ChemoSen↑, Keap1↑, NRF2↓,
4901- DCA,  Sal,    Dichloroacetate and Salinomycin as Therapeutic Agents in Cancer
- Review, NSCLC, NA
Glycolysis↓, OXPHOS↑, PDKs↓, ROS↑, Apoptosis↑, GlucoseCon↓, lactateProd↓, RadioS↑, TumAuto↑, mTOR↓, LC3s↓, p62↑, TumCG↓, OS↑, toxicity↝, ChemoSen↑, eff↑, eff↑, Ferritin↓, CSCs↓, EMT↓, ROS↑, Cyt‑c↑, Casp3↑, ER Stress↑, selectivity↑, eff↑, TumCG↓,
4920- PEITC,  Cisplatin,    PEITC restores chemosensitivity in cisplatin-resistant non-small cell lung cancer by targeting c-Myc/miR-424-5p
- vitro+vivo, NSCLC, A549
TumCG↓, ChemoSen↑, cMyc↓, PI3K↓, Akt↓, mTOR↓, BioAv↝, tumCV↓, ChemoSen↑,
5103- SK,    Attenuation of PI3K-Akt-mTOR Pathway to Reduce Cancer Stemness on Chemoresistant Lung Cancer Cells by Shikonin and Synergy with BEZ235 Inhibitor
- in-vitro, NSCLC, A549
CSCs↓, TumCP↓, Nanog↓, OCT4↓, p‑Akt↓, P70S6K↓, PI3K↓, mTOR↓, eff↑,

Showing Research Papers: 1 to 4 of 4

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 4

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

Keap1↑, 1,   NRF2↓, 1,   OXPHOS↑, 1,   ROS↑, 3,  

Metal & Cofactor Biology ⓘ

Ferritin↓, 1,  

Core Metabolism/Glycolysis ⓘ

cMyc↓, 1,   GlucoseCon↓, 1,   Glycolysis↓, 1,   lactateProd↓, 1,   PDKs↓, 1,  

Cell Death ⓘ

Akt↓, 1,   p‑Akt↓, 1,   Apoptosis↑, 1,   Casp3↑, 1,   Cyt‑c↑, 1,  

Transcription & Epigenetics ⓘ

tumCV↓, 1,  

Protein Folding & ER Stress ⓘ

ER Stress↑, 1,  

Autophagy & Lysosomes ⓘ

LC3s↓, 1,   p62↑, 1,   TumAuto↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

CSCs↓, 3,   EMT↓, 1,   mTOR↓, 4,   Nanog↓, 1,   OCT4↓, 1,   P70S6K↓, 1,   PI3K↓, 2,   STAT3↓, 1,   TumCG↓, 3,  

Migration ⓘ

TumCP↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↝, 1,   ChemoSen↑, 4,   eff↑, 4,   RadioS↑, 1,   selectivity↑, 1,  

Clinical Biomarkers ⓘ

Ferritin↓, 1,  

Functional Outcomes ⓘ

AntiTum↑, 1,   OS↑, 1,   toxicity↝, 1,  
Total Targets: 39

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: mTOR, mammalian target of rapamycin
1 Ashwagandha(Withaferin A)
1 Dichloroacetate
1 salinomycin
1 Phenethyl isothiocyanate
1 Cisplatin
1 Shikonin
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:19  Cells:%  prod#:%  Target#:209  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page